SARS-CoV-2 infection, vaccination and course of antibody response in adults: a cohort study in Catalonia – BMC Medicine

Ward H, Whitaker M, Blume B, Tang SN, Atchison C, Darzi A, et al. Population-specific antibody responses after COVID-19 vaccination in 212,102 people. Nat Commun. 2022;13:907.

CAS article Google Scholar

Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmeron G, et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022;75:103805.

CAS article Google Scholar

Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med 2022. https://doi.org/10.1038/s41591-022-01721-6.

Dashdorj NJ, Wirz OF, Röltgen K, Haraguchi E, Buzzanco AS, Sibai M, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. cell host microbe. 2021;29:1738–1743.e4.

CAS article Google Scholar

Ruggiero A, Piubelli C, Calciano L, Accordini S, Valenti MT, Carbonare LD, et al. SARS-CoV-2 vaccination elicits unconventional IgM-specific responses in naïve and previously infected individuals with COVID-19. EBioMedicine. 2022;77:103888.

CAS article Google Scholar

Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, et al. Systemic and mucosal IgA responses are differentially induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection from subsequent infection. mucosal immunol. 2022. https://doi.org/10.1038/s41385-022-00511-0.

Dobaño C, Jiménez A, Rubio R, Alonso S, Ramírez-Morros A, Vidal M, et al. Spike-based COVID-19 immunization increases antibodies against the nucleocapsid antigen. translation res. 2022;240:26-32.

Article Google Scholar

Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection with or vaccination against SARS-CoV-2 lead to permanent immunity? Lancet Respir Med. 2021;9:1450-66.

CAS article Google Scholar

Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S et al. Declining immune responses against SARS-CoV-2 variants are a concern among Hong Kong vaccinates. eBiomedicine. 2022;77:103904.

CAS article Google Scholar

Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC, Marconi VC, et al. Efficacy of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations – Five Veterans Affairs Medical Centers, United States, February 1-6. Aug 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1294-9.

CAS article Google Scholar

Karachaliou M, Moncunill G, Espinosa A, Castaño-Vinyals G, Jiménez A, Vidal M, et al. Infection-induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia, Spain. Sci Rep. 2021;11:21571.

CAS article Google Scholar

Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in people with mild Covid-19. N Engl J Med 2020;383:1085-7.

Article Google Scholar

Zimmermann P, Curtis N. Factors influencing the immune response to vaccination. Clin Microbiol Rev 2019;32:e00084-18.

CAS article Google Scholar

Obón-Santacana M, Vilardell M, Carreras A, Duran X, Velasco J, Galván-Femenía I, et al. GCAT|Genomes for life: a prospective cohort study of the genomes of Catalonia. BMJ open. 2018;8:e018324.

Article Google Scholar

Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies against human coronaviruses. Nat Commun. 2021;12:4740.

CAS article Google Scholar

Dobaño C, Santano R, Jiménez A, Vidal M, Chi J, Rodrigo Melero N, et al. Immunogenicity and cross-reactivity of antibodies against the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. Transl Res J Lab Clin Med. 2021. https://doi.org/10.1016/j.trsl.2021.02.006.

ECDC. Interesting and worrying variants in the EU/EEA.

Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D, et al. Highly sensitive and specific multiplex antibody assays for the quantification of immunoglobulins M, A and G against SARS-CoV-2 antigens. J Clin Microbiol. 2021;59.

Catalan Ministry of Health. Catalan Ministry of Health Catalan Epidemiological Surveillance System.

Gerussi V, Peghin M, Palese A, Bressan V, Visintini E, Bontempo G, et al. Vaccination hesitation in Italian patients who have recovered from COVID-19 infection compared to influenza and Sars-Cov-2 vaccination. vaccinations. 2021;9:172.

CAS article Google Scholar

Nguyen LH, Joshi AD, Drew DA, Merino J, Ma W, Lo CH, et al. Self-reported COVID-19 vaccine hesitancy and uptake among participants of different racial and ethnic groups in the United States and the United Kingdom. Nat Commun. 2022;13:636.

CAS article Google Scholar

Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, et al. Immunity against SARS-CoV-2 up to 15 months after infection. iscience. 2022;25:103743.

CAS article Google Scholar

Dobaño C, Ramírez-Morros A, Alonso S, Vidal-Alaball J, Ruiz-Olalla G, Vidal M, et al. Persistence and baseline determinants of seropositivity and reinfection rates in healthcare workers up to 12.5 months after COVID-19. BMC Med 2021;19:155.

Article Google Scholar

Faro-Viana J, Bergman ML, Gonçalves LA, Duarte N, Coutinho TP, Borges PC, et al. Population homogeneity for antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only achieved after the second dose across all adult age groups. Nat Commun. 2022;13:140.

CAS article Google Scholar

Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijočević H, et al. Dynamics of spike- and nucleocapsid-specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13:153.

CAS article Google Scholar

Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Jabal KA, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. preprint. epidemiology; 2022.

Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Risk factors for long COVID: Analyzes of 10 longitudinal studies and electronic health records in the UK. Form. epidemiology. 2021

Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Studies app: a prospective, community-based, nested case-control study. Lancet Infect Dis. 2022;22:43-55.

CAS article Google Scholar

Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection results in a robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7:eabn8014.

CAS article Google Scholar

Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41:457-65.

CAS article Google Scholar

Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11:22777.

CAS article Google Scholar

Lafon E, Jäger M, Bauer A, Reindl M, Bellmann-Weiler R, Wilflingseder D, et al. Comparative analyzes of the IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. J Allergy Clinic Immunol. 2022;149:1242–1252.e12.

CAS article Google Scholar

Fraussen J. IgM responses after SARS-CoV-2 vaccination: Insights into protective and preexisting immunity. eBiomedicine. 2022;77:103922.

CAS article Google Scholar

Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Scientific Transl. Med. 2021;13:eabd2223.

CAS article Google Scholar

Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) after two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a phase 2, blinded, multicentre, randomized, controlled trial. Lancet. 2021;398:2258-76.

CAS article Google Scholar

Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 UK adults general population. Nat Microbiol. 2021;6:1140-9.

CAS article Google Scholar

Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related heterogeneity of immune response to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417-22.

CAS article Google Scholar

Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, et al. Effects of age, gender, serostatus, and underlying comorbidities on the humoral response after SARS-CoV-2 Pfizer BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;1-18.

Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The effect of smoking on the humoral response to COVID-19 vaccines: a systematic review of epidemiological studies. vaccinations. 2022;10:303.

CAS article Google Scholar

Mazereel V, Van Assche K, Detraux J, De Hert M. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021;8:444-50.

Article Google Scholar

Naruse H, Ito H, Izawa H, Sarai M, Ishii J, Sakaguchi E, et al. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease. J.Clin. Med. 2021;10:5498.

CAS article Google Scholar

Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, gender, obesity, and side effects. front immunol. 2021;12:779212.

CAS article Google Scholar